SI-BONE Begins Post-Market Clinical Experience of iFuse Implant Device

SI-BONE, Inc., a Cupertino, Calif.-based medical device company that is pioneering the use of a minimally invasive surgical device to treat the sacroiliac joint, announced that the initial post-market clinical experience of its iFuse implant system will be presented at upcoming 2010 minimally invasive spine surgery meetings, according to an SI-BONE news release.

SI-BONE has been working with several well-known spine surgeons with experience in low back pathologies, who are early adopters of new MIS technologies. Separately, these surgeons are working on the submission of manuscripts and abstracts to spine society meetings and peer-reviewed journals.  

Mark Reiley, MD, founder and Chief Medical Officer at SI-BONE, said in the release, "We are honored that our colleagues have agreed to bring their extensive clinical experience and patient-centric focus to our scientific efforts and dedication to ongoing improvements in our technology. We expect to benefit from their insights and expertise in understanding MIS SI Joint fusion as a frontline therapy for patients with unresolved low back symptoms refractory to conservative therapy. We will continue to reach out to other spine surgeons and referring specialists to encourage clinical evaluation of iFuse, and we look forward to their further contributions."

The iFuse Implant System is a commercially available device in the U.S. intended for fracture fixation of large bones and large bone fragments of the pelvis for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. The iFuse procedure uses a minimal incision for delivery and implantation of small, titanium implants, coated with a porous plasma spray that acts as an interference surface, designed to help decrease implant motion, according to the release.

Read the SI-BONE release on the iFuse Implant System.